The USFDA has approved apremilast , an oral drug , to treat plaque psoriasis of any severity level for the first time. Evidence The drug approval followed the ADVANCE Phase 3 clinical trial. Adults with mild to moderate plaque psoriasis were given 30 mg of apremilast twice weekly.
At week 16, five times as many treated adults achieved the primary endpoint i.e. Static Physician's Global Assessment response, compared to the patients who received a placebo (P < .0001). The drug has received approval for three indications: Adult patients with plaque psoriasis who are phototherapy or systemic therapy candidates Adult patients with active psoriatic arthritis Adult patients with Behçet's disease-related oral ulcers Adverse effects The adverse events reported in 5% of patients included: Diarrhea Headache Nausea Nasopharyngitis Source: FDA Do you think apremilast is an effective choice to…
